What is the recommended aciclovir dosing for herpes zoster in adults (including immunocompetent, immunosuppressed, and severe cases) and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Aciclovir Dosing for Herpes Zoster

For immunocompetent adults with herpes zoster, treat with aciclovir 800 mg orally five times daily for 7-10 days, initiated within 72 hours (ideally within 48 hours) of rash onset 1.

Adult Dosing by Clinical Scenario

Immunocompetent Adults (Standard Cases)

  • Oral aciclovir 800 mg five times daily for 7-10 days 1
  • Must initiate within 72 hours of rash onset for maximum benefit
  • Greatest efficacy when started within 48 hours 2
  • This regimen significantly reduces viral shedding, accelerates healing, decreases new lesion formation, and reduces acute pain severity 3, 2
  • May reduce postherpetic neuralgia incidence by 46% at 6 months 4

Important caveat: The 800 mg five times daily dose is superior to lower doses (400 mg five times daily showed no significant benefit over placebo) 3.

Severe Disease or Complications

  • Aciclovir 5-10 mg/kg IV every 8 hours for 5-7 days until clinical resolution 1
  • Use IV route for:
    • Disseminated infection
    • CNS involvement (encephalitis)
    • Visceral involvement (pneumonitis, hepatitis)
    • Patients requiring hospitalization

Immunosuppressed Adults (HIV-infected or other immunocompromise)

  • Aciclovir 10 mg/kg IV every 8 hours for severe immunosuppression 5
  • For patients not responding to aciclovir: Foscarnet 40-60 mg/kg IV three times daily for 7-10 days 5
  • Alternative oral option for adolescents/adults: Famciclovir 500 mg orally three times daily for 7-10 days 5

Pediatric Dosing

HIV-Infected or Immunocompromised Children

Mild to moderate immunosuppression:

  • Aciclovir 20 mg/kg orally (maximum 800 mg/dose) four times daily for 7-10 days or until no new lesions for 48 hours 5

Severe immunosuppression:

  • Aciclovir 10 mg/kg IV three times daily 5
  • Some experts use body surface area dosing: 500 mg/m² IV every 8 hours in children >1 year 5

Immunocompetent Children with Chickenpox (Varicella)

  • Aciclovir 20 mg/kg orally (maximum 800 mg/dose) four times daily for 5 days 1
  • Children >40 kg: use adult dose of 800 mg four times daily 1
  • Must initiate within 24 hours of rash onset 1
  • Note: Intravenous aciclovir is indicated for varicella in immunocompromised children 1, 6

For immunocompromised children with varicella/zoster: 10 mg/kg IV every 8 hours for 5 days effectively prevents visceral involvement and is well-tolerated 6, 7.

Renal Dose Adjustments

Critical consideration: Aciclovir requires dose modification in renal impairment 1.

Creatinine Clearance Standard Dose Adjusted Dose Interval
>25 mL/min 800 mg 5x daily 800 mg Every 4 hours
10-25 mL/min 800 mg 5x daily 800 mg Every 8 hours
0-10 mL/min 800 mg 5x daily 800 mg Every 12 hours

Hemodialysis patients: Administer additional dose after each dialysis session due to 60% reduction in plasma concentrations during 6-hour dialysis 1.

Geriatric patients: Higher plasma concentrations occur due to age-related renal decline; dose reduction required if underlying renal impairment present 1.

Key Clinical Pearls

  • Timing is critical: Treatment initiated >72 hours after rash onset has minimal benefit
  • Food doesn't matter: Aciclovir can be taken with or without food 1
  • Bioavailability decreases with dose: The 800 mg dose has lower bioavailability than smaller doses, but remains clinically superior 1, 3
  • Ocular involvement: Requires ophthalmology consultation 5
  • Aciclovir resistance: If suspected (particularly in immunocompromised patients with prolonged disease), switch to foscarnet 5

The evidence strongly supports the 800 mg five times daily regimen over lower doses, with multiple placebo-controlled trials demonstrating significant clinical benefit in reducing acute symptoms and potentially preventing postherpetic neuralgia 3, 2, 4.

Related Questions

What is the recommended oral acyclovir dosage for treating herpes zoster in adults, including adjustments for renal impairment and immunocompromised patients?
What is the recommended acyclovir dosing for an adult with herpes zoster involving the maxillary division without ocular involvement, and how should the dose be adjusted for renal impairment?
What is the appropriate aciclovir dosing regimen for a second episode of herpes zoster?
What is the appropriate acyclovir dosage and dosing frequency for an 80-year-old patient with herpes zoster (shingles)?
What are the recommended dosing regimens for aciclovir in adults and children for herpes simplex virus and varicella‑zoster virus infections, including severe disease, prophylaxis, and adjustments for renal impairment?
What is the appropriate emergency assessment and management for a lethargic infant?
What is the immediate medical management for a patient with first-degree atrioventricular (AV) block presenting with chest pain?
Is it safe to prescribe a codeine‑paracetamol‑caffeine tablet to a patient on dialysis?
With a B-type natriuretic peptide (BNP) level of 196 pg/mL (normal low cutoff <125 pg/mL), what is the appropriate management?
For an adult septic patient with a pulmonary abscess caused by a pan‑resistant gram‑negative non‑fermenter, how is inhaled colistimethate sodium administered, which formulations are marketed in Brazil, what is the average price per dose, and what is the recommended dosing schedule?
What is the likely diagnosis and appropriate treatment for a 2‑year‑old child with three days of fever (~102 °F), loss of appetite, vomiting, and a cough that started as a croup‑type bark and is now productive, with negative COVID‑19, influenza, and RSV tests?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.